Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, is establishing a Center of Excellence for cell and gene therapy in Stevenage, UK. The new UK subsidiary, Rentschler ATMP Ltd., will establish development and manufacturing capability in Advanced Therapy Medicinal Products (ATMPs).

The site is being set up at an existing facility run by the Cell and Gene Therapy Catapult through a collaboration. Rentschler plans to make a significant investment at the site in the next five years to set up state-of-the-art manufacturing of viral vectors for clinical supply and expects to be ready for cGMP manufacturing by 1H22.

Dr. Frank Mathias, CEO of Rentschler Biopharma, said, “With more than 1000 cell and gene therapies currently in clinical development, the demand for manufacturing capabilities and support is ever increasing. Leveraging our specific expertise in process development and manufacturing for challenging molecules with highest quality and within demanding timelines, we are ideally suited to implement this knowledge in the field of viral vector production for new modalities. Our well-planned move into this growing area of biopharmaceuticals fits well with our strategic plans to expand internationally – ensuring proximity to our clients and important biopharma hubs.”